Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEN-K vs CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride is a potassium supplement that replaces potassium ions in the body, essential for maintaining intracellular osmotic pressure, acid-base balance, and nerve conduction. It acts as a cofactor for numerous enzymes and is critical for myocardial and skeletal muscle contraction.
Calcium ion is essential for normal cell function, including muscle contraction, nerve transmission, and blood coagulation. It acts as a positive inotrope by increasing myocardial contractility and also corrects hypocalcemia.
Treatment and prevention of hypokalemia,Hypokalemia associated with diuretic therapy,Hypokalemia in patients with digitalis toxicity
Cardiac resuscitation (e.g., asystole, pulseless electrical activity) due to hyperkalemia, hypocalcemia, or calcium channel blocker overdose,Severe hypocalcemia,Treatment of hypermagnesemia,Treatment of calcium channel blocker overdose,Cardiopulmonary bypass,Intraoperative floppy iris syndrome (off-label)
10 m Eq (one tablet) orally once daily or as directed by physician.
IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min. May be repeated as needed based on serum calcium levels and clinical response.
Terminal elimination half-life is approximately 30-60 minutes; clinical context: short half-life necessitates frequent dosing for maintenance of potassium levels.
2-4 hours in patients with normal renal function; prolonged in renal impairment.
Potassium chloride is not metabolized; it is absorbed and excreted primarily by the kidneys. Approximately 90% is eliminated in urine, with the remainder in feces and sweat.
Calcium chloride dissociates to release calcium ions which are primarily regulated by the kidney; no significant hepatic metabolism.
Renal: >90% excreted unchanged by the kidneys; fecal: <5%
Primarily renal (80-90% as ionized calcium); minor fecal elimination (<10%).
Minimal (<10%); not significantly bound to plasma proteins.
Approximately 45-50% bound primarily to albumin.
Approximately 0.2-0.4 L/kg; reflects distribution primarily in extracellular fluid.
0.5-0.6 L/kg; primarily distributed in extracellular fluid.
Oral: 100% (potassium chloride is well absorbed); IV: 100%.
Not applicable; administered only intravenously. Oral calcium salts have variable bioavailability (25-40%).
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min, reduce dose by 50% and monitor serum potassium. Use with caution in mild impairment.
GFR 30-60 m L/min: Use with caution; monitor serum calcium and phosphate levels. GFR <30 m L/min: Avoid use or use only if benefit outweighs risk; reduce dose by 50% and monitor serum calcium and phosphate closely.
No specific adjustment; however, use with caution in severe hepatic impairment due to risk of hyperkalemia.
No dose adjustment recommended for Child-Pugh Class A or B. Child-Pugh Class C: Use with caution; monitor serum calcium and cardiac function due to potential for accumulation of calcium and effects on myocardial contractility.
Not established; safety and efficacy in pediatric patients not determined.
IV: 0.2 m L/kg (20 mg/kg) of 10% solution, administered slowly at a rate not exceeding 0.5-1 m L/min. Dose may be repeated if needed. Maximum single dose: 1 g (10 m L).
Start at 5 m Eq orally daily; titrate slowly and monitor serum potassium due to age-related renal function decline.
No specific dose adjustment, but consider reduced renal function common in elderly; use lowest effective dose and monitor serum calcium, phosphate, and cardiac status. Infusion rate should be slow (0.5-1 m L/min) to avoid adverse effects.
None
Do not administer by intracardiac injection due to risk of myocardial rupture and cardiac arrest.
Hyperkalemia risk, especially in patients with renal impairment,Cardiac effects: risk of arrhythmias with rapid correction or high doses,Gastrointestinal reactions: ulceration, bleeding, perforation with solid oral formulations,Use with caution in patients with renal insufficiency, adrenal insufficiency, diabetes, or cardiac disease,Monitor serum potassium levels and ECG during therapy
Extravasation can cause tissue necrosis; administer slowly to avoid hypercalcemia; use with caution in digitalis toxicity as hypercalcemia potentiates digoxin toxicity; monitor serum calcium levels; avoid in patients with renal failure unless severe hypocalcemia exists.
Hyperkalemia,Severe renal impairment with oliguria or anuria,Untreated Addison's disease,Solid oral potassium supplements in patients with delayed gastrointestinal transit
Hypercalcemia, ventricular fibrillation during cardiac arrest, concurrent digitalis therapy (relative), patients with known hypersensitivity to calcium salts.
Avoid high-potassium foods (bananas, oranges, spinach, potatoes, tomatoes) in large amounts; limit salt substitutes containing potassium chloride. Take with food to minimize GI irritation.
Avoid calcium-fortified foods and dairy products if serum calcium is elevated. High doses of vitamin D can increase calcium absorption, leading to hypercalcemia. Caffeine and alcohol may increase urinary calcium excretion, potentially reducing efficacy. Oxalate-rich foods (spinach, rhubarb) and phytate-rich foods (whole grains) bind calcium and may reduce absorption, but this is less relevant with IV administration.
No known teratogenic effects based on available data. Potassium supplementation does not increase risk of congenital anomalies above baseline. However, avoid hyperkalemia in pregnant women as high potassium levels may pose risks. First trimester: No evidence of fetal harm. Second trimester: Monitor maternal potassium levels. Third trimester: Adjusted potassium requirements may occur due to increased renal clearance; maintain normokalemia.
No evidence of teratogenicity in animal studies; calcium chloride is a normal blood constituent. First trimester: no known risk. Second and third trimesters: use only if clearly needed; high doses may cause hypercalcemia in fetus (e.g., hypotonia, poor feeding). Intravenous administration near term may suppress fetal parathyroid function.
Potassium is excreted into breast milk in amounts not likely to cause adverse effects in nursing infants. The M/P ratio is approximately 0.4. Supplementation at physiological doses is considered compatible with breastfeeding. Monitor maternal serum potassium to avoid excessive dosage.
Calcium is excreted in breast milk but in normal physiological amounts. M/P ratio not established; supplemental calcium likely safe but high IV doses may increase milk calcium concentration. Monitor infant for hypercalcemia with prolonged high-dose maternal therapy.
No specific dose adjustment required for TEN-K based on pregnancy alone. However, pregnancy can increase renal clearance of potassium, potentially lowering serum levels. Monitor potassium levels and adjust dose if hypokalemia develops. Typical dose range: 20-100 m Eq/day, titrated according to serum potassium. Avoid excessive dosing to prevent hyperkalemia.
No specific dose adjustment required; pharmacokinetic changes in pregnancy (e.g., increased plasma volume) may necessitate higher doses to achieve desired serum calcium levels, but titrate to effect and serum calcium monitoring. Avoid bolus administration during labor; use slow IV infusion.
TEN-K is a high-dose potassium chloride formulation (10 m Eq per tablet) used for hypokalemia. Do not split or crush tablets; they are extended-release to prevent GI irritation. Monitor serum potassium and renal function; avoid in severe renal impairment or hyperkalemia. Consider potential for esophageal ulceration if tablet lodges.
Calcium chloride provides approximately 3 times more elemental calcium per m L than calcium gluconate. Due to its high osmolality (approx. 2000 m Osm/L), it is a severe vesicant; central line administration is strongly preferred to prevent tissue necrosis if extravasation occurs. For peripheral IV, use a large bore vein with good blood flow and avoid hand/wrist veins. In cardiac arrest (e.g., hyperkalemia, calcium channel blocker overdose), give 10 m L of 10% solution (1 g) IV push; may repeat every 10 minutes if needed. Monitor serum calcium, magnesium, and phosphate levels; correct hypomagnesemia before calcium therapy to prevent refractory hypocalcemia. Contraindicated in digitalis toxicity (can precipitate fatal arrhythmias). Not for IM or SC use.
Take with a full glass of water and with food or after a meal to reduce stomach upset.,Swallow tablets whole; do not crush, chew, or split them.,Avoid salt substitutes or potassium-containing supplements unless directed by your doctor.,Report signs of hyperkalemia: muscle weakness, irregular heartbeat, tingling in hands/feet.,Store at room temperature, away from moisture and heat.
Report any burning, pain, or swelling at the IV site immediately.,This medication increases calcium levels; do not take additional calcium supplements or antacids without doctor approval.,Calcium can interfere with the absorption of certain antibiotics (tetracyclines, fluoroquinolones) and thyroid medications; separate doses by at least 2-4 hours.,Avoid excessive intake of vitamin D or calcium-rich foods unless directed by your doctor.,Seek emergency care if you experience chest pain, irregular heartbeat, or muscle cramps.
No interactions on record
"Calcium chloride, an intravenous calcium salt, directly increases serum ionized calcium levels, which can antagonize the pharmacodynamic effects of the calcium channel blocker manidipine. Manidipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. Elevated extracellular calcium from calcium chloride administration can overcome this blockade, potentially diminishing the antihypertensive efficacy of manidipine and increasing the risk of hypertensive urgency or elevated blood pressure."
"Calcium chloride, a source of calcium ions, can chelate with bisphosphonates such as risedronic acid in the gastrointestinal tract, forming insoluble complexes that reduce the oral absorption of risedronic acid. This interaction may lead to decreased serum concentrations of risedronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption. Patients may experience reduced bone mineral density or increased risk of fractures if the interaction is significant."
"Calcium chloride, a source of calcium ions, can chelate alendronic acid (a bisphosphonate) in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of alendronic acid. This interaction can significantly decrease the systemic bioavailability and serum concentration of alendronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption and treating osteoporosis. Clinically, patients may experience reduced bone mineral density improvement or increased fracture risk if the drugs are co-administered."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEN-K vs CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, answered by our medical review team.
TEN-K is a Electrolyte supplement that works by Potassium chloride is a potassium supplement that replaces potassium ions in the body, essential for maintaining intracellular osmotic pressure, acid-base balance, and nerve conduction. It acts as a cofactor for numerous enzymes and is critical for myocardial and skeletal muscle contraction.. CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Calcium ion is essential for normal cell function, including muscle contraction, nerve transmission, and blood coagulation. It acts as a positive inotrope by increasing myocardial contractility and also corrects hypocalcemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEN-K and CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEN-K is: 10 m Eq (one tablet) orally once daily or as directed by physician.. The standard adult dose of CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is: IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min. May be repeated as needed based on serum calcium levels and clinical response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEN-K and CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEN-K is classified as Category C. No known teratogenic effects based on available data. Potassium supplementation does not increase risk of congenital anomalies above baseline. However, avoid hyperkalemia in pregna. CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies; calcium chloride is a normal blood constituent. First trimester: no known risk. Second and third trimesters: use only if clearly ne. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.